Life Sciences Partners (LSP) has reached a first close of its third fund at E65m. LSP III is dedicated to life science investments in Europe, with a focus on the Benelux and Germany. All major investors of the previous LSP funds committed to LSP III, including, among others, the European Investment Fund, Residex and DSM. The fund also received commitments from a number of new investors in Germany, Switzerland, Luxembourg and Finland.
LSP III will invest in between 15 and 20 companies active in the life science area in the Benelux, Germany and the rest of Europe, following the strategy of its previous funds. Martijn Kleijwegt, managing partner at LSP, says: “We feel proud of having been able to establish LSP III in the current difficult market. We are particularly pleased with the new high quality investors participating in LSP III, including SwissRe, Finnish Industry Investment, Proventure and BGL Investment Partners.”
Based in Amsterdam and Munich, LSP has been investing in the human life sciences for over 15 years. Since inception, LSP’s management has invested in 40 life science companies, of which 13 have successfully completed their IPO or merged with leading companies in the industry.